Candel TherapeuticsCADL
13F holders, Q1 2024 (March 31)20holders
1famous investor
$1.58avg. 13F price*
At the end of Q1 2024, 20 institutions reported holding Candel Therapeutics Inc. (CADL) in their 13F filings. The largest holders were Northpond Ventures, LLC ($3.1M), Sands Capital Alternatives, LLC ($1.3M) and Vanguard Group Inc. ($855K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Candel Therapeutics Inc.
- CUSIP
- 137404109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $123K |
| Exits | 5 | $502K |
Ownership 20 holders
| Northpond Ventures, LLC | 2.98% | No change | 1,935,215 | $3.1M |
| Sands Capital Alternatives, LLC | 0.31% | No change | 811,737 | $1.3M |
| Vanguard Group Inc. | 0.00% | Add +27.1% | 541,295 | $855K |
| Geode Capital Management, LLC | 0.00% | Add +4.6% | 145,706 | $230K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -37.7% | 82,595 | $131K |
| Renaissance Technologies | 0.00% | Add +204.7% | 56,905 | $90K |
| BlackRock Inc. | 0.00% | Reduce -3.5% | 47,580 | $75K |
| Mariner, LLC | 0.00% | New | 33,480 | $53K |
| OneDigital Investment Advisors LLC | 0.00% | No change | 29,783 | $47K |
| State Street Corp. | 0.00% | No change | 27,600 | $44K |
| Northern Trust Corp. | 0.00% | Reduce -0.6% | 19,507 | $31K |
| Traphagen Investment Advisors LLC | 0.00% | New | 17,215 | $27K |
| Commonwealth Equity Services, LLC | 0.00% | New | 14,182 | $22K |
| Two Sigma Investments, LP | 0.00% | New | 13,409 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -45.0% | 3,702 | $6K |
| JPMorgan Chase & Co. | 0.00% | Add +5.7% | 221 | $349 |
| Wells Fargo & Company | 0.00% | Add +1.8% | 115 | $182 |
| UBS Group AG | 0.00% | Reduce -99.9% | 10 | $16 |
| Qube Research & Technologies Ltd | 0.00% | No change | 1 | $2 |
| Royal Bank of Canada | 0.00% | Add +130.0% | 69 | $0 |
"% of holder's portfolio" is CADL's weight in each manager's 13F, not the share of Candel Therapeutics Inc. the manager owns.